Ovr115 antibody compositions and methods of use

Abstract

The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.

1 . An isolated Ovr115 antibody that competes for binding to the same epitope as the epitope bound by the monoclonal antibody produced by a hybridoma selected from the group consisting of ATCC accession number PTA-5202, PTA-5916, PTA-5917, PTA-5918, PTA-5919 and PTA-5920. 
     
     
         2 . The antibody of  claim 1  which internalizes upon binding to Ovr115 on a mammalian cell in vivo. 
     
     
         3 . The antibody of  claim 1  which is a monoclonal antibody, an antibody fragment, a chimeric, or a humanized or human antibody. 
     
     
         4 - 7 . (canceled) 
     
     
         8 . The antibody of  claim 1  which inhibits Ovr115 activity. 
     
     
         9 . The antibody of  claim 8  wherein Ovr115 activity is protease activity. 
     
     
         10 . The antibody of  claim 1  which is conjugated to a growth inhibitory agent or a cytotoxic agent. 
     
     
         11 - 23 . (canceled) 
     
     
         24 . A cell that produces the antibody of  claim 1 . 
     
     
         25 - 26 . (canceled) 
     
     
         27 . A composition comprising the antibody of  claim 1 , and a carrier. 
     
     
         28 . The composition of  claim 27 , wherein the antibody is conjugated to a cytotoxic agent. 
     
     
         29 - 31 . (canceled) 
     
     
         32 . A method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with the antibody of  claim 1 , thereby killing the cancer cell. 
     
     
         33 . The method of  claim 32 , wherein the cancer cell is selected from the group consisting of ovarian, pancreatic and colon cancer cell. 
     
     
         34 . (canceled) 
     
     
         35 . The method of  claim 33 , wherein the ovarian, pancreatic or colon cancer is ovarian epithelial cancer, pancreatic epithelial cancer, colon epithelial cancer, ovarian serous adenocarcinoma or colon adenocarcinoma. 
     
     
         36 . The method of  claim 33 , wherein the cancer cell is from metastatic ovarian, pancreatic or colon cancer. 
     
     
         37 - 38 . (canceled) 
     
     
         39 . The method of  claim 32 , wherein the antibody is conjugated to a cytotoxic agent. 
     
     
         40 . The method of  claim 39 , wherein the cytotoxic agent is a radioactive isotope or a toxin selected from the group consisting of maytansinoid, ricin, saporin and calicheamicin. 
     
     
         41 - 42 . (canceled) 
     
     
         43 . A method of alleviating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the antibody of  claim 1  to the mammal. 
     
     
         44 . The method of  claim 43 , wherein the cancer is selected from the group consisting of ovarian, pancreatic and colon cancer. 
     
     
         45 . The method of  claim 44 , wherein the ovarian, pancreatic or colon cancer is ovarian epithelial cancer, pancreatic epithelial cancer, colon epithelial cancer, ovarian serous adenocarcinoma or colon adenocarcinoma. 
     
     
         46 . (canceled) 
     
     
         47 . The method of  claim 43 , wherein the antibody is conjugated to a cytotoxic agent. 
     
     
         48 - 50 . (canceled) 
     
     
         51 . An article of manufacture comprising a container and a composition contained therein, wherein the composition comprises an antibody of  claim 1 . 
     
     
         52 - 67 . (canceled) 
     
     
         68 . A screening method for antibodies of  claim 1  comprising,
 (a) combining an Ovr115-containing sample with a test antibody and an antibody produced by a hybridoma selected from the group consisting of American Type Culture Collection accession number PTA-5202, PTA-5916, PTA-5917, PTA-5918, PTA-5919 and PTA-5920 to form a mixture, 
 (b) determining the level of Ovr115 antibody bound to Ovr115 in the mixture and 
 (c) comparing the level of Ovr115 antibody bound in the mixture of step (a) to a control mixture, 
 wherein the level of Ovr115 antibody binding to Ovr115 in the mixture as compared to the control is indicative of the test antibody's binding to an epitope that is bound by the anti-Ovr115 antibody of  claim 1 . 
 
     
     
         69 - 73 . (canceled)